Europeiska unionen - danska - EMA (European Medicines Agency)

amgen europe b.v. - romiplostim - purpura, trombocytopenisk, idiopatisk - antihemorrhagics - adults:nplate is indicated for the treatment of primary immune thrombocytopenia  (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunglobuliner). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroider, immunglobuliner).

Danmark - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

grifols deutschland gmbh - normalt immunoglobulin til intravenøs brug, humant - infusionsvæske, opløsning - 100 mg/ml

Danmark - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

octapharma ab - normalt immunglobulin, humant - infusionsvæske, opløsning - 100 mg/ml

Danmark - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

csl behring gmbh - anti-d immunglobulin, humant - injektionsvæske, opløsning i fyldt injektionssprøjte - 300 mikrogram

Danmark - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

instituto grifols s.a. - normalt immunoglobulin til intravenøs brug, humant - injektionsvæske, opløsning - 200 mg/ml

Europeiska unionen - danska - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Europeiska unionen - danska - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosuppressiva - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Europeiska unionen - danska - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - medicin for obstruktiv sygdomme, - allergiske asthmaxolair er indiceret hos voksne, unge og børn (6 til.

Europeiska unionen - danska - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiske midler - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Europeiska unionen - danska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiske midler - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.